CD38 Antibody Market Surges: Biotech's Next Gold Rush
Baca dalam 60 detik
- CD38 antibodies target a glycoprotein overexpressed in hematologic cancers, with daratumumab already generating over $8 billion annually.
- Clinical trials now explore combinations with CAR-T and bispecifics, potentially doubling addressable patient populations.
- This strategy reduces resistance rates and extends treatment durability.
CD38 antibodies target a glycoprotein overexpressed in hematologic cancers, with daratumumab already generating over $8 billion annually. Clinical trials now explore combinations with CAR-T and bispecifics, potentially doubling addressable patient populations. This strategy reduces resistance rates and extends treatment durability.
Pipeline assets from MorphoSys and Takeda target earlier treatment lines, aiming to capture first-line therapy market share. Regulatory filings in China and Europe accelerate global expansion, with biosimilar threats looming by 2030. Patent expirations will force innovators to defend through combination therapies and subcutaneous formulations.
Market dynamics favor companies with strong manufacturing capabilities and real-world evidence generation. The shift toward fixed-duration regimens lowers cumulative costs while maintaining efficacy, appealing to payers. Analysts project a compound annual growth rate exceeding 12% through 2034.
Power Move: The CD38 antibody market isn't just growing—it's fragmenting into specialized niches. Innovators who master early-line positioning and combination regimens will dominate. Biosimilar entrants must wait: originators still hold the clinical data edge.
This article was edited with AI assistance for readability. Read original here.
